Study guide
19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance
UEMS European Board of Dermatovenereology Diploma Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Eligibility & Examination Regulations
1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition
2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology
2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns
3 Chapter 3: Dermatopathology & Diagnostic Procedures
3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy
4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology
4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance
5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease
5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders
6 Chapter 6: Hair, Nails & Pigmentary Disorders
6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation
7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease
7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses
8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease
8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease
9 Chapter 9: Autoimmune Bullous Diseases
9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis
10 Chapter 10: Eczematous Disorders, Urticaria & Allergology
10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy
11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis
11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses
12 Chapter 12: Paediatric & Genetic Dermatology
12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa
13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections
13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections
14 Chapter 14: Viral & Fungal Cutaneous Infections
14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses
15 Chapter 15: Sexually Transmitted Infections & Genital Infections
15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis
16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine
16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems
17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours
17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases
18 Chapter 18: Melanocytic Naevi & Melanoma
18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma
19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas
19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas
20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing
20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy
21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures
21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy
22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision
22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review
19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance
Key Takeaways Explain This Topic AI
Short-term sequential digital dermoscopy, repeated after about 3 months, is used for flat equivocal melanocytic lesions without melanoma-specific features, and any significant change leads to excision.
Reflectance confocal microscopy uses near-infrared light (about 830 nm) to produce horizontal images with near-cellular resolution to a depth of about 200 to 250 micrometres.
Organ transplant recipients have a roughly 65- to 100-fold increased risk of cutaneous squamous cell carcinoma, and switching to an mTOR inhibitor or starting low-dose acitretin can reduce new tumours in high-risk patients.
In the ONTRAC trial, oral nicotinamide 500 mg twice daily reduced new keratinocyte cancers by about 23% in immunocompetent high-risk patients, but a later trial in transplant recipients showed no significant benefit.
Since 2008, people aged 35 and older with German statutory health insurance have been entitled to a skin cancer screening examination every 2 years.
Last updated: September 2026
19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance
Dermoscopy itself is covered in the dermoscopy chapter. This section covers the other imaging tools and how they are used for surveillance.
Sequential Digital Dermoscopy and Total Body Photography
Tool How It Is Used When to Excise
Short-term sequential digital dermoscopy Repeat dermoscopic images after about 3 months for single flat , equivocal melanocytic lesions without melanoma-specific features Any significant change in structure, colour, or asymmetric growth
Long-term digital follow-up Images every 6–12 months for many naevi in high-risk patients New structures, asymmetric enlargement, regression, new colours
Total body photography (2D or 3D) Whole-body images to detect new or changing lesions ; combined with digital dermoscopy ("two-step" surveillance) New lesions in adults, or change in existing ones
Nodular, raised, or rapidly growing lesions must not be monitored. They need excision, because nodular melanoma can grow fast.
Reflectance Confocal Microscopy (RCM)
Uses near-infrared laser light (about 830 nm ) to produce horizontal (en face) grey-scale images with near-cellular resolution , down to about 200–250 µm (the papillary dermis).
Melanocytic lesions: melanoma shows pagetoid cells and atypical cells at the dermo-epidermal junction, with loss of the normal honeycomb pattern. RCM added to dermoscopy reduces benign excisions .
Lentigo maligna: helps diagnosis and mapping margins on the face.
Basal cell carcinoma: tumour islands with polarised nuclei and peripheral palisading.
Ex vivo confocal microscopy can assess margins during micrographic surgery.
Optical Coherence Tomography (OCT)
Produces vertical (cross-sectional) images to a depth of about 1–2 mm with lower resolution than RCM.
Best for keratinocyte tumours : diagnosing and subtyping BCC, monitoring non-surgical treatment, and assessing actinic keratoses. Dynamic OCT shows vessels.
Line-field confocal OCT combines vertical and horizontal imaging at cellular resolution.
High-Frequency Ultrasound (HFUS)
Probes of about 20–100 MHz image the skin and subcutis.
Uses: preoperative tumour depth (BCC, melanoma), inflammatory disease (morphoea activity, hidradenitis suppurativa , where ultrasound finds subclinical tunnels and collections and refines staging), nails, and cysts.
Lymph node ultrasound is more sensitive than palpation for detecting nodal recurrence and is part of melanoma follow-up for higher-risk stages in European guidance.
Measuring Skin Function
- Measurement What It Shows
- Transepidermal water loss (TEWL) Barrier function; raised in atopic dermatitis and irritant dermatitis
- Corneometry Stratum corneum hydration
- Sebumetry Sebum output
- Colorimetry and spectrophotometry Erythema and pigmentation, for example in phototesting
- Skin surface pH Barrier and microbiome environment
- Elasticity (cutometer) Mechanical properties, for example in scleroderma or ageing
These measurements are mainly used in research, clinical trials, and occupational dermatology.
Teledermatology and Artificial Intelligence
Store-and-forward teledermatology sends clinical and dermoscopic images for specialist review. It is widely used for triaging suspected skin cancer. Live (real-time) consultations suit follow-up and inflammatory disease.
Artificial intelligence (AI) classifiers can match specialists on selected image datasets. In the EU, diagnostic AI software is regulated as a medical device (Medical Device Regulation), and the EU AI Act classes medical AI as high-risk.
Limitations: performance falls with images unlike the training data ( dataset shift ), with underrepresented skin types , and with rare diagnoses. Clinicians remain responsible and must keep human oversight .
Skin Cancer Screening
Germany runs a national programme: since 2008, people with statutory health insurance aged 35 and older can have a skin cancer screening examination every 2 years . The regional SCREEN pilot in Schleswig-Holstein was followed by lower melanoma mortality, but this was not reproduced nationally, and no randomised trial has proven a mortality benefit for population screening.
Concerns: overdiagnosis of thin melanomas and cost.
Targeted surveillance is widely recommended for high-risk people: over about 100 naevi or several atypical naevi, previous melanoma, two or more affected first-degree relatives or a known CDKN2A mutation, organ transplant recipients , genodermatoses such as xeroderma pigmentosum, and fair-skinned people with heavy sun damage.
Euromelanoma is a pan-European awareness and screening campaign run by dermatologists.
Surveillance of Organ Transplant Recipients (OTRs)
Solid organ transplant recipients have a roughly 65- to 100-fold increased risk of cutaneous squamous cell carcinoma , which is often multiple, aggressive, and more likely to metastasise. The usual BCC:SCC ratio is reversed.
Skin examinations: before transplantation, then at least yearly; every 3–6 months once skin cancer has developed.
Prevention: strict photoprotection; field treatment of actinic keratoses (5-fluorouracil, photodynamic therapy); and early treatment of all lesions.
Chemoprevention: low-dose acitretin for patients with multiple SCCs. The benefit is lost when it is stopped.
Immunosuppression: in agreement with the transplant team, switching from calcineurin inhibitors to an mTOR inhibitor (sirolimus or everolimus) reduces new SCCs in patients who have already had skin cancer. Azathioprine increases UVA photosensitivity. Long-term voriconazole (phototoxic) is associated with SCC and should be avoided where possible.
Nicotinamide: in the ONTRAC trial, 500 mg twice daily reduced new keratinocyte cancers by about 23% in immunocompetent high-risk patients. A later trial in transplant recipients did not show a significant benefit.